TRIB2 and nasopharyngeal carcinoma: This pathway elucidates a mechanism by which cystatin A inhibits NPC cell motility and metastasis, suggesting the cystatin A‐METTL3 axis as a potential therapeutic target for NPC.[136] Furthermore, METTL14 modulates TRIB2 expression through miR‐99a‐5p, targeting TRIB2 mRNA for degradation in ESCC.